|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis.
|
31198407 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We found that Wee1 expression increased in the direction of malignancy, and showed a strong, positive correlation with known biomarkers involved in cell cycle regulation: Cyclin A (p<0.0001), Ki67 (p<0.0001), Cyclin D3 (p = 0.001), p21(Cip1/WAF1) (p = 0.003), p53 (p = 0.025).
|
22719872 |
2012 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
|
21555162 |
2011 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Genomic changes disrupting the expression of cyclin D3 are associated with aberrant growth of several human B-lymphoid malignancies.
|
20107311 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This dataset reveals 20 genes that are specifically mutated in either p19(ARF)-deficient, p53-deficient or wild-type mice (including Flt3, mmu-mir-106a-363, Smg6, and Ccnd3), as well as networks of significant collaborative and mutually exclusive interactions between cancer genes.
|
18485879 |
2008 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Although it is known that t(6;14)(p21;q32) induces aberrant overexpression of CCND3 in B-cell malignancies, we were able to show that CCND3, which encodes the cyclin D family member protein that controls the G1-S phase of cell cycle regulation, can also be a target of genomic gain/amplification.
|
16322284 |
2005 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cyclin D3 overexpression was noted the earliest in pancreatic intraepithelial neoplasia-1A and was prevalent in 90% to 100% of high-grade pancreatic intraepithelial neoplasias and ductal cancer.
|
15475449 |
2004 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin D3 IR was positively associated with p27 IR (P =.004) but not with Ki-67 LI or tumor malignant potential.
|
13679452 |
2003 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data implicate CCND3 as a dominant oncogene in the pathogenesis and transformation in several histologic subtypes of mature B-cell malignancies with t(6;14)(p21.1;q32.3) and suggest that CCND3 overexpression seen in about 10% of DLBCL cases may have a genetic basis.
|
11675358 |
2001 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although cyclin D3 was ubiquitously expressed, its expression was reduced in lymphoid malignancies with cyclin D1 or D2 overexpression.
|
10482983 |
1999 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In pulmonary carcinomas, distinct expression of the cyclin D3 protein is unlikely to be implicated in tumorigenesis, because of its expression in only a small fraction of cancer cells.It may relate to cancer progression.
|
8688970 |
1996 |
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTCH1-driven mouse models of this disease with a CDK4/6 small-molecule inhibitor.
|
28151717 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
|
28671688 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
While cyclin D3 expression contributes to cell-cycle progression in Notch-dependent human T-ALL cell lines, ectopic expression of CDK4 or CDK6 together with cyclin D3 shows partial rescue from gamma-secretase inhibitor (GSI)-induced G(1) arrest in these cell lines.
|
19001083 |
2009 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.
|
17300668 |
2007 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Cyclin D3 mediates synthesis of a hyaluronan matrix that is adhesive for monocytes in mesangial cells stimulated to divide in hyperglycemic medium.
|
19276076 |
2009 |
|
Mammary Neoplasms, Experimental
|
0.200 |
Biomarker
|
phenotype |
RGD |
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
|
16311245 |
2006 |
|
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions.
|
30698716 |
2019 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with squamous NSCLC, a performance status of 0 to 2, and normal organ function who had progressed after at least one prior platinum-based chemotherapy with cyclin-dependent kinase 4 gene (CDK4) or cyclin D1 gene (CCND1), cyclin D2 gene (CCND2), or cyclin D3 gene (CCND3) amplifications on tumor specimens were eligible.
|
31302234 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
But, its prognostic role of cyclin D3 in neoplasms remains controversial.
|
31198407 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A miR-194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma.
|
31301177 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
High density lipoprotein measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions.
|
30698716 |
2019 |